Alluvi, formerly BI 4744, offers a promising development in weight control care. This dual agonist targeting both GLP-1 and GIP receptors demonstrates remarkable effectiveness in patient trials, possibly exceeding https://alluvi756457.veronicablog.com/63173289/alluvi-a-in-depth-investigation-into-the-medication-s-prospects